查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
體外診斷市場至2030年預測：按產品/服務、技術、應用、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383359

體外診斷市場至2030年預測：按產品/服務、技術、應用、最終用戶和地區進行的全球分析

Invitro Diagnostics Market Forecasts to 2030 - Global Analysis By Product and Service, Technology, Application, End User and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球體外診斷市場規模為 981.4 億美元，預計到2030年將達到 1,485.4 億美元，預測期內年複合成長率為 6.1%。

體外診斷是指使用血液、尿液和組織等生物樣本的一類醫學檢查和診斷技術。這些測試用於監測和識別自體免疫疾病、感染疾病和各種其他醫療狀況。它也用於分析藥物治療的變化。此外，它還可以準確、及時地進行診斷，有助於改善健康狀況、降低醫療成本、防止疾病傳播。

根據國際糖尿病聯盟（IDF）的資料，2021年全球有 5.37 億人患有糖尿病，預計到2030年將增加至 6.43 億人。

新興國家對早期診斷的認知不斷增強

新興國家對早期疾病診斷的認知不斷提高，成為體外製藥市場的關鍵促進因素。隨著這些地區醫療保健意識和教育的提高，越來越多的人尋求預防性醫療保健措施和疾病的早期發現。早期診斷通常會帶來更好的治療效果、降低醫療成本並改善整體健康。這種意識不僅使個人受益，還鼓勵衛生系統和政府投資於診斷基礎設施，推動對體外診斷產品和服務的需求。此外，隨著新興國家擴大醫療保健覆蓋範圍，對具有成本效益且易於使用的診斷解決方案的需求不斷增加，滿足這一需求推動體外診斷領域的創新和市場成長。

高成本

開發、製造和購買體外藥物測試和設備所包括的成本可能很高。這些成本通常會轉嫁給醫療保健提供者和患者，導致經濟挑戰。償付不足和醫療保健預算有限進一步加劇了經濟負擔。因此，獲得基本診斷服務的機會可能會減少，特別是在資源匱乏的地區，疾病的早期發現和管理可能會受到阻礙。因此，這將阻礙市場需求。

技術進步

診斷技術的持續創新透過提高準確性、效率和可及性徹底改變醫療保健。分子診斷、晶片實驗室平台和晶載次世代定序等先進技術可實現更快、更準確的測試結果。攜帶式和即時檢測設備的發展使診斷更加方便，特別是在偏遠和資源有限的地區。此外，體外藥物與數位健康平台和人工智慧的整合將進一步增強資料分析和解釋。這些進步不僅改善了病患護理，也降低了醫療成本。投資研發以利用這些技術的體外診斷公司可以獲得競爭優勢，並開拓新興市場以獲得尖端診斷解決方案。

嚴格的法規和法律標準

嚴格的法規和法律指南對體外診斷市場構成重大威脅。這些指南通常是為了確保診斷測試的安全性和有效性而實施的，但可能會導致合規成本增加、核准流程更長以及體外診斷製造商的市場進入障礙。違規還可能導致罰款和產品召回。此外，不斷變化的法規可能使公司難以適應不斷變化的標準，影響產品開發和創新。

COVID-19 的影響

在 COVID-19大流行期間，多個行業都受到了積極和消極的影響。分子診斷的使用增加對市場產生了正面影響，抵消了其他類別的負面影響。此外，對檢測套組和消耗品的需求不斷成長，以監測住院的 COVID-19 患者的血糖值和肌鈣蛋白濃度。由於分子和即時檢測銷售額的大幅成長，參與公司的收益大幅成長。然而，全球醫院和實驗室進行的常規檢測大幅減少，導致一些大公司的收益利潤率下降。

預計糖尿病領域在預測期內將是最大的領域

預計糖尿病領域將佔最大佔有率。糖尿病是一種慢性代謝疾病，代表了體外診斷市場的重要部分。糖尿病的診斷測試對於疾病的早期發現、監測和管理非常重要。糖尿病體外藥品市場包括血糖值監測設備、HbA1c 測試以及評估血糖值的各種其他測試。隨著全球糖尿病盛行率持續上升，該領域穩步成長。此外，體外診斷的創新幫助患者和醫療保健專業人員有效控制糖尿病、減少併發症、提高數百萬糖尿病患者的生活品質，為雙方提供準確、便捷的工具發揮重要作用。

預計臨床實驗室部門在預測期內年複合成長率最高

預計臨床實驗室部門在預測期內將出現良好成長。臨床實驗室是體外診斷市場的基本部分。這些專業設施對血液、尿液和組織等患者樣本進行各種診斷測試，以幫助診斷、治療和監測疾病。臨床實驗室在醫療保健中發揮關鍵作用，為醫療保健提供者提供決策所需的關鍵資訊。此外，臨床實驗室提供廣泛的測試，包括化學、微生物學、血液學、免疫學和分子診斷。由於對準確、及時的患者照護和醫療服務的需求不斷增加，臨床實驗室行業不斷成長。

佔有率最大的地區

在估計期間，亞太地區佔據最大的市場佔有率。亞太地區是全球體外診斷市場中快速成長且充滿活力的部門。該地區是中國、印度和日本等人口眾多的多元化國家的所在地，衛生基礎設施顯著擴張，衛生支出也在增加。促成該成長的因素包括疾病盛行率上升、早期疾病檢測意識增強以及獲得醫療保健服務的機會增加。此外，政府舉措和監管改革提高診斷測試的品質和可及性。隨著檢測需求的激增，COVID-19 大流行也凸顯了該地區體外診斷的重要性。

年複合成長率最高的地區：

由於完善的醫療保健行業和不斷增加的慢性病數量，預計北美在預測期內將實現盈利成長。該地區的特點是競爭形勢，擁有雅培實驗室、賽默飛世爾科技和羅氏診斷等知名公司。此外，該市場致力於研究和開發，引進尖端的診斷測試和技術。美國FDA 等監管機構負責確保品質和安全標準。此外，COVID-19 大流行凸顯了體外診斷測試對該地區感染疾病診斷、追蹤和管理的重要性。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球體外診斷市場：依產品與服務分類

  • 介紹
  • 試劑和套件
  • 裝置
  • 服務
  • 資料管理軟體

第6章 全球體外診斷市場：依技術分類

  • 介紹
  • 免疫檢測/免疫化學
  • 血液學
  • 微生物學
  • 尿液檢查
  • 臨床化學
  • 分子診斷
  • 凝血和止血
  • 其他技術

第7章 全球體外診斷市場：依應用分類

  • 介紹
  • 感染疾病
  • 藥物測試/藥物基因組學
  • 腫瘤學
  • HIV愛滋病
  • 糖尿病
  • 自體免疫疾病
  • 心臟病學
  • 腎臟病學
  • 其他用途

第8章 全球體外診斷市場：依最終用戶分類

  • 介紹
  • 醫院實驗室
  • 學術機構
  • 病人
  • 即時檢測中心
  • 臨床實驗室
  • 其他最終用戶

第9章 全球體外診斷市場：依地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Freenome Holdings, Inc.
  • Agilent Technologies, Inc.
  • Natera, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Sysmex Corporation
  • Siemens Healthineers AG
  • BD（Becton, Dickinson, and Company）
  • Quest Diagnostics Incorporated
  • Bio-Rad Laboratories, Inc.
  • Alere, Inc.
  • InterVenn Biosciences
  • Guardant Health
  • Thermo Fisher Scientific, Inc.
  • NeoGenomics Laboratories
  • Invitae Corporation
  • Beckman Coulter
  • Danaher
  • Illumina, Inc.
Product Code: SMRC24209

According to Stratistics MRC, the Global In vitro Diagnostics Market is accounted for $98.14 billion in 2023 and is expected to reach $148.54 billion by 2030 growing at a CAGR of 6.1% during the forecast period. In vitro diagnostics (IVD) refers to a category of medical tests and diagnostic techniques on biological samples such as blood, urine, and tissues. These tests are used to monitor and identify autoimmune diseases, infectious diseases, and a variety of other medical conditions. They may also be used to analyse changes in drug therapy. Moreover, they enable precise and timely diagnoses, contributing to improved health outcomes, reduced healthcare costs, and the prevention of disease spread.

According to the International Diabetes Federation (IDF), in 2021, there were 537 million people across the globe suffering from diabetes, and the number is expected to increase to 643 million by 2030.

Market Dynamics:

Driver:

Increasing awareness of early disease diagnosis in emerging economies

The growing awareness of early disease diagnosis in emerging economies stands out as a significant driver of the in vitro diagnostics (IVD) market. As healthcare awareness and education improve in these regions, more people are seeking preventive healthcare measures and early disease detection. Early diagnosis often results in better treatment outcomes, reduced healthcare costs, and improved overall health. This awareness not only benefits individuals but also prompts healthcare systems and governments to invest in diagnostic infrastructure, thus boosting the demand for IVD products and services. Moreover, as emerging economies expand their healthcare access, there is a greater need for cost-effective and accessible diagnostic solutions, driving innovation and market growth in the IVD sector to meet these demands.

Restraint:

High cost

The expenses associated with developing, producing, and procuring IVD tests and equipment can be substantial. These costs are often passed on to healthcare providers and patients, leading to affordability challenges. Inadequate reimbursement and limited healthcare budgets further exacerbate the financial burden. This can result in reduced access to essential diagnostic services, particularly in resource-constrained settings, hindering early disease detection and management. Therefore, this will hamper market demand.

Opportunity:

Technological advancements

Continuous innovation in diagnostic technologies is revolutionising healthcare by enhancing accuracy, efficiency, and accessibility. Advanced techniques, such as molecular diagnostics, lab-on-a-chip platforms, and next-generation sequencing, allow for quicker and more precise test results. The development of portable and point-of-care testing devices makes diagnostics more convenient, especially in remote or resource-limited areas. Additionally, the integration of IVD with digital health platforms and artificial intelligence further enhances data analysis and interpretation. These advancements not only improve patient care but also reduce healthcare costs. IVD companies that invest in research and development to leverage these technologies can gain a competitive edge and tap into the expanding market for cutting-edge diagnostic solutions

Threat:

Stringent regulations and legal standards

Stringent regulatory and legal guidelines pose a significant threat to the in vitro diagnostics (IVD) market. These guidelines often imposed to ensure the safety and efficacy of diagnostic tests, can lead to increased compliance costs, lengthy approval processes, and market entry barriers for IVD manufacturers. Non-compliance can result in fines and product recalls. Additionally, evolving regulations can make it challenging for companies to keep up with changing standards, impacting product development and innovation.

COVID-19 Impact

During the COVID-19 pandemic, several segments witnessed both positive and negative effects. The market experienced a positive impact due to the increased use of molecular diagnostics, which counteracted the negative effects of other categories. Furthermore, among hospitalised COVID-19 patients, there was a rise in the need for test kits and consumables for monitoring blood glucose and troponin levels. Participants have experienced a significant increase in sales of molecular and point-of-care tests, which has resulted in a significant increase in their earnings. However, a significant drop in routine testing carried out in hospitals and laboratories globally caused some major firms to see a dip in their revenue margins.

The Diabetes segment is expected to be the largest during the forecast period

The Diabetes segment is estimated to hold the largest share. Diabetes, a chronic metabolic disorder, represents a significant segment of the in vitro diagnostics (IVD) market. Diagnostic tests for diabetes are vital for the early detection, monitoring, and management of the condition. The IVD market for diabetes includes blood glucose monitoring devices, HbA1c tests, and various other assays for assessing blood sugar levels. As the global prevalence of diabetes continues to rise, this segment experiences consistent growth. Furthermore, IVD innovations play a crucial role in delivering precise and convenient tools for both patients and healthcare professionals to effectively control diabetes, reduce complications, and enhance the quality of life for millions of individuals affected by the disease.

The Clinical Laboratories segment is expected to have the highest CAGR during the forecast period

The Clinical Laboratories segment is anticipated to have lucrative growth during the forecast period. Clinical laboratories are a fundamental segment of the in vitro diagnostics (IVD) market. These specialised facilities conduct various diagnostic tests on patient samples, such as blood, urine, and tissue, to aid in disease diagnosis, treatment, and monitoring. They play a crucial role in healthcare, providing essential information to healthcare providers for decision-making. Moreover, clinical laboratories offer a wide range of tests, including chemistry, microbiology, haematology, immunology, and molecular diagnostics. The clinical laboratory industry is growing due to the growing need for accurate and timely patient care as well as the need for healthcare services.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region represents a rapidly growing and dynamic sector within the global in vitro diagnostics (IVD) market. With diverse and populous countries, such as China, India, and Japan, this region is witnessing significant expansion in healthcare infrastructure and increasing healthcare expenditures. Factors contributing to the growth include rising disease prevalence, increasing awareness of early disease detection, and growing access to healthcare services. Moreover, government initiatives and regulatory reforms are driving quality and accessibility in diagnostic testing. The COVID-19 pandemic has also emphasised the importance of IVD in the region, with a surge in demand for testing.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to the well-established healthcare industry and the rising prevalence of chronic diseases. The region is characterised by a competitive landscape with prominent companies like Abbott Laboratories, Thermo Fisher Scientific, and Roche Diagnostics. Moreover, the market benefits from a strong focus on research and development, leading to the introduction of cutting-edge diagnostic tests and technologies. Regulatory bodies, such as the FDA in the United States, ensure quality and safety standards. Additionally, the COVID-19 pandemic has underscored the importance of IVD tests in the region for diagnosing, tracking, and managing infectious diseases.

Key players in the market

Some of the key players in the In vitro Diagnostics Market include: Freenome Holdings, Inc., Agilent Technologies, Inc., Natera, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Sysmex Corporation, Siemens Healthineers AG, BD (Becton, Dickinson, and Company), Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., Alere, Inc., InterVenn Biosciences, Guardant Health, Thermo Fisher Scientific, Inc., NeoGenomics Laboratories, Invitae Corporation, Beckman Coulter, Danaher and Illumina, Inc.

Key Developments:

In May 2023, Freenome, a privately held biotech company, announced that it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures.

In November 2022, Thermo Fisher Scientific (US) launched the rapid RT-PCR Accula Flu A/Flu B Test designed to enable healthcare providers to detect and differentiate influenza A and B in about 30 minutes.

In October 2022, Thermo Fisher Scientific (US) entered a definitive agreement to acquire The Binding Site Group, a global leader in specialty diagnostics. The Binding Site provides specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders.

In September 2022, Sysmex Corporation (Japan) launched the UF-1500 Fully Automated Urine Particle Analyzer (UF-1500) for urine sediment testing. The UF-1500 inherits the high levels of functionality and usability of the UF-5000 Fully Automated Urine Particle Analyzer (UF-5000).

In August 2022, Al-Futtaim Health (Dubai) and Abbott Laboratories (US) entered into a strategic partnership to improve the standards of advanced laboratory diagnostics in Dubai.

Product and Services Covered:

  • Reagents & Kits
  • Instruments
  • Services
  • Data Management Software

Technologies Covered:

  • Immunoassay/ Immunochemistry
  • Hematology
  • Microbiology
  • Urinalysis
  • Clinical Chemistry
  • Molecular Diagnostics
  • Coagulation and Hemostasis
  • Other Technologies

Applications Covered:

  • Infectious Diseases
  • Drug Testing/ Pharmacogenomics
  • Oncology
  • HIV/AIDS
  • Diabetes
  • Autoimmune Diseases
  • Cardiology
  • Nephrology
  • Other Applications

End Users Covered:

  • Hospital Laboratories
  • Academic Institutes
  • Patients
  • Point-of-Care Testing Centers
  • Clinical Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Invitro Diagnostics Market, By Product and Service

  • 5.1 Introduction
  • 5.2 Reagents & Kits
  • 5.3 Instruments
  • 5.4 Services
  • 5.5 Data Management Software

6 Global Invitro Diagnostics Market, By Technology

  • 6.1 Introduction
  • 6.2 Immunoassay/ Immunochemistry
  • 6.3 Hematology
  • 6.4 Microbiology
  • 6.5 Urinalysis
  • 6.6 Clinical Chemistry
  • 6.7 Molecular Diagnostics
  • 6.8 Coagulation and Hemostasis
  • 6.9 Other Technologies

7 Global Invitro Diagnostics Market, By Application

  • 7.1 Introduction
  • 7.2 Infectious Diseases
  • 7.3 Drug Testing/ Pharmacogenomics
  • 7.4 Oncology
  • 7.5 HIV/AIDS
  • 7.6 Diabetes
  • 7.7 Autoimmune Diseases
  • 7.8 Cardiology
  • 7.9 Nephrology
  • 7.10 Other Applications

8 Global Invitro Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospital Laboratories
  • 8.3 Academic Institutes
  • 8.4 Patients
  • 8.5 Point-of-Care Testing Centers
  • 8.6 Clinical Laboratories
  • 8.7 Other End Users

9 Global Invitro Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Freenome Holdings, Inc.
  • 11.2 Agilent Technologies, Inc.
  • 11.3 Natera, Inc.
  • 11.4 Exact Sciences Corporation
  • 11.5 F. Hoffmann-La Roche Ltd.
  • 11.6 Abbott Laboratories
  • 11.7 Sysmex Corporation
  • 11.8 Siemens Healthineers AG
  • 11.9 BD (Becton, Dickinson, and Company)
  • 11.10 Quest Diagnostics Incorporated
  • 11.11 Bio-Rad Laboratories, Inc.
  • 11.12 Alere, Inc.
  • 11.13 InterVenn Biosciences
  • 11.14 Guardant Health
  • 11.15 Thermo Fisher Scientific, Inc.
  • 11.16 NeoGenomics Laboratories
  • 11.17 Invitae Corporation
  • 11.18 Beckman Coulter
  • 11.19 Danaher
  • 11.20 Illumina, Inc.

List of Tables

  • Table 1 Global Invitro Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Invitro Diagnostics Market Outlook, By Product and Service (2021-2030) ($MN)
  • Table 3 Global Invitro Diagnostics Market Outlook, By Reagents & Kits (2021-2030) ($MN)
  • Table 4 Global Invitro Diagnostics Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 5 Global Invitro Diagnostics Market Outlook, By Services (2021-2030) ($MN)
  • Table 6 Global Invitro Diagnostics Market Outlook, By Data Management Software (2021-2030) ($MN)
  • Table 7 Global Invitro Diagnostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 8 Global Invitro Diagnostics Market Outlook, By Immunoassay/ Immunochemistry (2021-2030) ($MN)
  • Table 9 Global Invitro Diagnostics Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 10 Global Invitro Diagnostics Market Outlook, By Microbiology (2021-2030) ($MN)
  • Table 11 Global Invitro Diagnostics Market Outlook, By Urinalysis (2021-2030) ($MN)
  • Table 12 Global Invitro Diagnostics Market Outlook, By Clinical Chemistry (2021-2030) ($MN)
  • Table 13 Global Invitro Diagnostics Market Outlook, By Molecular Diagnostics (2021-2030) ($MN)
  • Table 14 Global Invitro Diagnostics Market Outlook, By Coagulation and Hemostasis (2021-2030) ($MN)
  • Table 15 Global Invitro Diagnostics Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 16 Global Invitro Diagnostics Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Invitro Diagnostics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 18 Global Invitro Diagnostics Market Outlook, By Drug Testing/ Pharmacogenomics (2021-2030) ($MN)
  • Table 19 Global Invitro Diagnostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 20 Global Invitro Diagnostics Market Outlook, By HIV/AIDS (2021-2030) ($MN)
  • Table 21 Global Invitro Diagnostics Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 22 Global Invitro Diagnostics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 23 Global Invitro Diagnostics Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 24 Global Invitro Diagnostics Market Outlook, By Nephrology (2021-2030) ($MN)
  • Table 25 Global Invitro Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 26 Global Invitro Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Invitro Diagnostics Market Outlook, By Hospital Laboratories (2021-2030) ($MN)
  • Table 28 Global Invitro Diagnostics Market Outlook, By Academic Institutes (2021-2030) ($MN)
  • Table 29 Global Invitro Diagnostics Market Outlook, By Patients (2021-2030) ($MN)
  • Table 30 Global Invitro Diagnostics Market Outlook, By Point-of-Care Testing Centers (2021-2030) ($MN)
  • Table 31 Global Invitro Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 32 Global Invitro Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.